Just nine months after bringing Zecuity to market, Teva Pharmaceuticals has suspended all sales activity surrounding their new migraine relief patch. This includes marketing as well as distribution.
Zecuity’s launch has gone far worse than expected for Teva. The FDA issued a safety alert regarding the migraine relief patch earlier this month after a “large number of patients” experienced burns and scarring on the patch site.
Zecuity was intended ...
continue reading...